Trial Profile
A phase I safety, pharmacodynamic and pharmacokinetic study of ABM-125
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 23 May 2017
Price :
$35
*
At a glance
- Drugs LNR 125.38 (Primary)
- Indications Asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 23 May 2017 New trial record